Invesaro

Stocks HALO Earnings

Earnings

Halozyme Therapeutics, Inc. (HALO) earnings

Quarterly results of Halozyme Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when HALO files with the SEC.

Next earnings date

Halozyme Therapeutics, Inc. is expected to report around January 27, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Halozyme Therapeutics, Inc. reported revenue of $493M (+39.2% on the same quarter a year earlier) and net income of $247M (+41% on the same quarter a year earlier).

Diluted earnings per share were $2.01 (+40.6% on the same quarter a year earlier).

Filed with the SEC on November 5, 2026.

Revenue by quarter
Q4 24: $298M $298M Q4 24Q1 25: $264.9M $264.9M Q1 25Q2 25: $325.7M $325.7M Q2 25Q3 25: $354.3M $354.3M Q3 25Q4 25: $451.8M $451.8M Q4 25Q1 26: $376.7M $376.7M Q1 26Q2 26: $481M $481M Q2 26Q3 26: $493M $493M Q3 26
Net income by quarter
Q4 24: $137M $137M Q4 24Q1 25: $118.1M $118.1M Q1 25Q2 25: $165.2M $165.2M Q2 25Q3 25: $175.2M $175.2M Q3 25Q4 25: -$141.6M -$141.6M Q4 25Q1 26: $150M $150M Q1 26Q2 26: $229.9M $229.9M Q2 26Q3 26: $247M $247M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026$493M+39.2%$247M$2.01
Q2 FY2026June 30, 2026$481M+47.7%$229.9M$1.90
Q1 FY2026March 31, 2026$376.7M+42.2%$150M$1.22
Q4 FY2025December 31, 2025$451.8M+51.6%-$141.6M-
Q3 FY2025September 30, 2025$354.3M-$175.2M$1.43
Q2 FY2025June 30, 2025$325.7M-$165.2M$1.33
Q1 FY2025March 31, 2025$264.9M-$118.1M$0.93
Q4 FY2024December 31, 2024$298M-$137M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Halozyme Therapeutics, Inc.'s next earnings date?

Halozyme Therapeutics, Inc. is expected to report around January 27, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Halozyme Therapeutics, Inc.'s latest quarterly results?

For Q3 FY2026, which ended September 30, 2026, Halozyme Therapeutics, Inc. reported revenue of $493M and net income of $247M (+41% on the same quarter a year earlier). The figures come from its filing with the SEC.

Is Halozyme Therapeutics, Inc.'s revenue growing?

Revenue in Q3 FY2026 was $493M, up 39.2% from $354.3M in the same quarter a year earlier.

Get an email when HALO reports

Follow HALO and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when HALO files with the SEC.

Source: quarterly figures Halozyme Therapeutics, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Halozyme Therapeutics, Inc.